Table 20.

Strength of evidence of pharmacotherapy for SAD

Agent	Level of evidence	Agent	Level of evidence
Antidepressants
SSRIs [58,426-429]	1	TCAs
Escitalopram [430-432]	1	Clomipramine [458,459]	3
Fluvoxamine [433-435]	1	Imipramine [460]	3 (-ve)
Fluvoxamine CR [436,437]	1	MAOIs and RIMAs
Paroxetine [431,438-444]	1	Phenelzine [384,386,418,461,462]	1
Sertraline [445-448]	1	Moclobemide [417,462-466]	1*
Fluoxetine [382,387,449]	1*	Other antidepressants
Citalopram [450,451]	2	Mirtazapine [467,468]	1*
Paroxetine CR [452]	2	Bupropion SR [469]	3
Adjunctive paroxetine [453]	3
SNRIs
Venlafaxine XR [439,441,454,255,456]	1
Duloxetine [457]	2
Other therapies
Anxiolytics		Anticonvulsants
Benzodiazepines		Pregabalin [474,475]	1
Clonazepam [385,470,471]	1	Gabapentin [476,477]	2
Alprazolam [386]	2	Levetiracetam [478-480]	2 (-ve)
Bromazepam [472]	2	Divalproex [481]	3
Adjunctive clonazepam [473]	2 (-ve)	Tiagabine [477,482]	3
		Topiramate [483]	3
Other treatments		Atypical antipsychotics
Atenolol [461,484]	1 (-ve)	Olanzapine [493]	2
Buspirone [383,485]	1 (-ve)	Quetiapine [494,495]	2 (-ve)
Atomoxetine [486,487]	1*	Adjunctive aripiprazole [496]	3
Propranolol [488]	2 (-ve)	Adjunctive risperidone [271]	3
Selegiline [489]	3
Pergolide [490]	3 (-ve)
Adjunctive buspirone [491]	3
Adjunctive pindolol [492]	2 (-ve)

*Conflicting data. CR = controlled release; MAOI = monoamine oxidase inhibitor; RIMA = reversible inhibitor of monoamine oxidase A; SNRI = serotonin–norepinephrine reuptake inhibitor; SR = sustained release; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; XR = extended release; (-ve) = negative.